0001808805-23-000029.txt : 20230301 0001808805-23-000029.hdr.sgml : 20230301 20230301171833 ACCESSION NUMBER: 0001808805-23-000029 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230227 FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Godwin Mary E. CENTRAL INDEX KEY: 0001439716 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39434 FILM NUMBER: 23695023 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE CITY: SEATTLE STATE: WA ZIP: 98121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nautilus Biotechnology, Inc. CENTRAL INDEX KEY: 0001808805 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2701 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-333-2001 MAIL ADDRESS: STREET 1: 2701 EASTLAKE AVE EAST CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp III DATE OF NAME CHANGE: 20200408 4 1 wf-form4_167770909041820.xml FORM 4 X0306 4 2023-02-27 0 0001808805 Nautilus Biotechnology, Inc. NAUT 0001439716 Godwin Mary E. C/O NAUTILUS BIOTECHNOLOGY, INC. 2701 EASTLAKE AVE. EAST SEATTLE WA 98102 0 1 0 0 Senior VP, Operations Stock Option (Right to Buy) 2.0 2023-02-27 4 A 0 160000 0 A 2033-02-27 Common Stock 160000.0 160000 D Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023. /s/ Matthew B. Murphy, as Attorney-in-Fact 2023-03-01